Molecular analysis of the multidrug transporter, P-glycoprotein

Cytotechnology

Volumn 27, Issue 1-3, 1998, Pages 31-60

  Germann, Ursula A ^a   Chambers, Timothy C ^b  

^a VERTEX PHARMACEUTICALS   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

ATP binding cassette; ATPase; Drug transport; Multidrug resistance; P glycoprotein; Phosphorylation

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; BIOSYNTHESIS; CANCER; CHOLESTEROL; DRUG TRANSPORT; GLYCOPROTEIN P; ION CHANNEL; MAMMAL CELL; MOLECULAR ANALYSIS; MULTIDRUG RESISTANCE; PLASMA PROTEIN; PROTEIN PHOSPHORYLATION; TUMOR CELL;

MAMMALIA;

EID: 0032439160     PISSN: 09209069     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-017-2374-9_2     Document Type: Article

References (271)

1. Abraham EH, Prat AG, Gerweck L, Seneveratne T, Arceci RJ, Kramer R, Guidotti G and Cantiello HF (1993) The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc Natl Acad Sci USA 90: 312-316.
2. Aftab DT, Yang JM and Hait WN (1994) Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. Oncol Res 6: 59-70.
3. Ahmad S and Glazer RI (1993) Expression of the antisense cDNA for protein kinase-C-alpha attenuates resistance in doxorubicinresistant MCF-7 breast carcinoma cells. Mol Pharmacol 43: 858-862.
4. Ahmad S, Safa AR and Glazer RI (1994) Modulation of P-glycoprotein by protein kinase C alpha in a baculovirus expression system. Biochemistry 33: 10313-10318.
5. Akiyama S-i, Cornwell MM, Kuwano M, Pastan I and Gottesman MM (1988) Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol. Pharmacol. 33: 144-147.
6. Al-Shawi MK and Senior AE (1993) Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein. J Biol Chem 268: 4197-4206.
7. Al-Shawi MK, Urbatsch IL and Senior AE (1994) Covalent inhibitors of P-glycoprotein ATPase activity. J Biol Chem 269: 8986-8992.
8. Altenberg GA, Vanoye CG, Horton JK and Reuss L (1994) Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc Natl Acad Sci USA 91: 4654-4657.
9. Ambudkar SV, Lelong IH, Zhang JP, Cardarelli CO, Gottesman MM and Pastan I (1992) Partial purification and reconstitution of the human multidrug resistance pump - characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci. USA 89: 8472-8476.
10. Ambudkar SV (1995) Purification and reconstitution of functional human P-glycoprotein. J Bioenerg Biomembr 27: 23-29.
11. Ambudkar SV, Cardarelli CO, Pashinsky I and Stein WD (1997) Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J Biol Chem 272: 21160-21166.
12. Ames GF-L, Mimura CS, Holbrook SR and Shyamala V (1992) Traffic ATPases: a superfamily of transport proteins operating from Escherichia coli to humans. Adv Enzymol 65: 1-47.
13. Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan RC, Smith AE and Welsh MJ (1991) Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253: 202-205.
14. Arias IM (1993) Is the multidrug resistance an ATP channel. Hepatology 18:216-217.
15. Arsenault AL, Ling V and Kartner N (1988) Altered plasma membrane ultrastructure in multidrug-resistant cells. Biochim Biophys Acta 938: 315-321.
16. Ayesh S, Shao YM and Stein WD (1996) Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1316: 8-18.
17. Azzaria M, Schurr E and Gros P (1989) Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol Cell Biol 9: 5289-5297.
18. Bates SE, Currier SJ, Alvarez M and Fojo AT (1992) Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 31: 6366-6372.
19. Bates SE, Lee JS, Dickstein B, Spolyar M and Fojo AT (1993) Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry 32: 9156-9164.
20. Baubichon-Cortay H, Baggetto LG, Dayan G and Di Pietro A (1994) Overexpression and purification of the carboxyl-terminal nucleotide-binding domain from mouse P-glycoprotein. J Biol Chem 269: 22983-22989.
21. Beaudet L and Gros P (1995) Functional dissection of P-glycoprotein nucleotide binding domains in chimeric and mutant proteins. J Biol Chem 270: 17159-17170.
22. Beck WT and Danks MK (1991) Characteristics of multidrug resistance in human tumor cells. In: Roninson, IB (ed) Molecular and cellular biology of multidrug resistance in tumor cells (pp. 3-46. Plenum Publishing Corporation: New York.
23. Beck WT and Qian X-D (1992) Photoaffinity substrates for Pglycoprotein. Biochem Pharmacol 43: 89-93.
24. Béja O and Bibi E (1995) Multidrug resistance protein (Mdr)alkaline phosphatase hybrids in Escherichia coli suggest a major revision in the topology of the C-terminal half of Mdr. J Biol Chem 270: 12351-12354.
25. Bellamy WT (1996) P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 36: 161-183.
26. Bibi E and Béja O (1994) Membrane topology of multidrug resistance protein expressed in Escherichia coli. J Biol Chem 269: 19910-19915.
27. Biedler JL and Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30: 1174-1184.
28. Boer R, Dichtl M, Borchers C, Ulrich WR, Marecek JF, Prestwich GD, Glossmann H and Striessnig J (1996a) Reversible labeling of a chemosensitizer binding domain of P- glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor. Biochemistry 35: 1387-1396.
29. Boer R, Ulrich WR, Haas S, Borchers C, Gekeler V, Boss H, Przybylski M and Schodl A (1996b) Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein. Eur J Pharmacol 295: 253-260.
30. Borchers C, Ulrich WR, Klemm K, Ise W, Gekeler V, Haas S, Schodl A, Conrad J, Przybylski M and Boer R (1995) B9209-005, an azido derivative of the chemosensitizer dexniguldipine-HCl, photolabels P-glycoprotein. Mol Pharmacol 48: 21-29.
31. Borgnia MJ, Eytan GD and Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271: 3163-3171.
32. Borst P and Schinkel AH (1996) What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer 32A: 985-990.
33. Borst P and Schinkel AH (1997) Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet 13: 217-222.
34. Boscoboinik D, Debanne MT, Stafford AR, Jung CY, Gupta RS and Epand RM (1990) Dimerization of the P-glycoprotein in membranes. Biochim Biophys Acta 1027: 225-228.
35. Bradley G, Juranka PF and Ling V (1988) Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87-128.
36. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SP and Sehested M (1995) Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 55:459-462.
37. Brown PC, Thorgeirsson SS and Silverman JA (1993) Cloning and regulation of the rat mdr2 gene. Nucleic Acids Res 21: 3885-3891.
38. Bruggemann EP, Germann UA, Gottesman MM and Pastan I (1989) Two different regions of P-glycoprotein are photoaffinity labeled by azidopine. J Biol Chem 264: 15483-15488.
39. Bruggemann EP, Currier SJ, Gottesman MM and Pastan I (1992) Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 267: 21020-21026.
40. Busche R, Tummler B, Riordan JR and Cano-Gauci DE (1989) Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug resistance. Mol Pharmacol 35: 414-421.
41. Buschman E and Gros P (1991) Functional analysis of chimeric genes obtained by exchanging homologous domains of the mouse mdr1 and mdr2 genes. Mol Cell Biol 11: 595-603.
42. Buschman E, Arceci RJ, Croop JM, Che M, Arias IM, Housman DE and Gros P (1992) mdr2 encodes P-glycoprotein expressed in the bile canalicular membrane as determined by isoform-specific antibodies. J Biol Chem 267: 18093-18099.
43. Cardarelli CO, Aksentijevich I, Pastan I and Gottesman MM (1995) Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (VI85) multidrug transporters. Cancer Res 55: 1086-1091.
44. Chambers TC, McAvoy EM, Jacobs JW and Eilon G (1990) Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 265: 7679-7686.
45. Chambers TC, Zheng B and Kuo JF (1992) Regulation by phorbol ester and protein kinase-C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human-KB cells. Mol Pharmacol 41: 1008-1015.
46. Chambers TC and Kuo JF (1993) Phosphorylation and regulation of P-glycoprotein by protein kinase C. In: Miyazaki, T., Takaku, F. and Sakurada, K. (eds) The mechanism and new approach on drug resistance of cancer cells (pp. 159-166). Elsevier Science Publishers: Amsterdam.
47. Chambers TC, Pohl J, Raynor RL and Kuo JF (1993) Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase-C. J Biol Chem 268: 4592-4595.
48. Chambers TC, Pohl J, Glass DB and Kuo JF (1994) Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein. Biochem J 299: 309-315.
49. Chambers TC, Germann UA, Gottesman MM, Pastan I, Kuo JF and Ambudkar SV (1995) Bacterial expression of the linker region of human MDR1 P-glycoprotein and mutational analysis of phosphorylation sites. Biochemistry: 14156-14162.
50. Chambers TC (1996) Phosphorylation of proteins involved in multidrug resistance. In: Gupta, S. and Tsuruo, T. (eds) Multidrug resistance in cancer cells (pp. 303-318). John Wiley & Sons: Chichester, U.K.
51. Chaudhary P and Roninson IB (1992) Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol Res 4: 281-290.
52. Chen C-J, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM and Roninson IB (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389.
53. Chen G, Duran GE, Steger KA, Lacayo NJ, Jaffrezou JP, Dumontet C and Sikic BI (1997) Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem 272: 5974-5982.
54. Childs S and Ling V (1994) The MDR superfamily of genes and its biological implications. Important Adv Oncol 1994: 21-36.
55. Choi K, Chen C-J, Kriegler M and Roninson IB (1989) An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 53: 519-529.
56. Cianfriglia M, Willingham MC, Tombesi M, Scagliotti GV, Frasca G and Chersi A (1994) P-glycoprotein epitope mapping. I. Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multi-drug-resistant cells. Int J Cancer 56: 153-160.
57. Cianfriglia M, Poloni F, Signoretti C, Romagnoli G, Tombesi M and Felici F (1996) Topology of MDR1-P-glycoprotein as indicated by epitope mapping of monoclonal antibodies to human MDR cells. Cytotechnology 19: 247-251.
58. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR and Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287.
59. Cornwell MM (1996) Regulation of MDR genes. In: Gupta S and Tsuruo T (eds) Multidrug resistance in cancer cells (pp. 39-48) John Wiley & Sons, Chichester, U.K.
60. Cornwell MM, Gottesman MM and Pastan I (1986a) Increased vinblastine binding to membrane vesicles from multidrug resistant KB cells. J Biol Chem 262: 7921-7928.
61. Cornwell MM, Safa AR, Felsted RL, Gottesman MM and Pastan I (1986b) Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150-170 kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci USA 83: 3847-3850.
62. Cornwell MM, Tsuruo T, Gottesman MM and Pastan I (1987) ATP-binding properties of P-glycoprotein from multidrug resistant KB cells. FASEB J 1: 51-54.
63. Cornwell MM, Pastan I and Gottesman MM (1991) Binding of drugs and ATP by P-glycoprotein and transport of drugs by vesicles from human multidrug-resistant cells. In: Roninson, I.B. (ed) Molecular and cellular biology of multidrug resistance in tumor cells (pp. 229-242). Plenum Publishing Corporation: New York.
64. Currier SJ, Ueda K, Willingham MC, Pastan I and Gottesman MM (1989) Deletion and insertion mutants of the multidrug transporter. J Biol Chem 264: 14376-14381.
65. Currier SJ, Kane SE, Willingham MC, Cardarelli CO, Pastan I and Gottesman MM (1992) Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters. J Biol Chem 267: 25153-25159.
66. Danø K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochem Biophys Acta 323: 466-483.
67. Dawidowicz EA (1987) Dynamics of membrane lipid metabolism and turnover. Annu Rev Biochem 56: 43-61.
68. Dayan G, Baubichon-Cortay H, Jault JM, Cortay JC, Deleage G and Di Pietro A (1996) Recombinant N-terminal nucleotide-binding domain from mouse P-glycoprotein. Overexpression, purification, and role of cysteine 430. J Biol Chem 271: 11652-11658.
69. Debry P, Nash EA, Neklason DW and Metherall JE (1997) Role of multidrug resistance P-glycoproteins in cholesterol esterification. J Biol Chem 272: 1026-1031.
70. Demeule M, Wenger RM and Beliveau R (1997) Molecular interactions of cyclosporin A with P-glycoprotein. Photolabeling with cyclosporin derivatives. J Biol Chem 272: 6647-6652.
71. Demmer A, Dunn T, Hoof T, Kubesch P and Tummler B (1996) Competitive inhibition of photoaffinity labelling of P-glycoprotein by anticancer drugs and modulators including S9788. Eur J Pharmacol 315: 339-343.
72. Deuchars KL, Duthie M and Ling V (1992) Identification of distinct P-glycoprotein gene sequences in rat. Biochim Biophys Acta 1130: 157-165.
73. Devault A and Gros P (1990) Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 10: 1652-1663.
74. Devine SE, Ling V and Melera PW (1992) Amino acid substitutions in the 6th transmembrane domain of P-glycoprotein alter multidrug resistance. Proc Natl Acad Sci USA 89: 4564-4568.
75. Devine SE and Melera PW (1994) Diversity of multidrug resistance in mammalian cells. J Biol Chem 269: 6133-6139.
76. Dhir R and Gros P (1992) Functional analysis of chimeric proteins constructed by exchanging homologous domains of two P-glycoproteins conferring distinct drug resistance profiles. Biochemistry 31: 6103-6110.
77. Doige CA, Yu XH and Sharom FJ (1992) ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochim Biophys Acta 1109: 149-160.
78. Doige CA, Yu XH and Sharom FJ (1993) The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim Biophys Acta 1146: 65-72.
79. Dong M, Penin F and Baggetto LG (1996) Efficient purification and reconstitution of P-glycoprotein for functional and structural studies. J Biol Chem 271: 28875-28883.
80. Endicott JA, Juranka PF, Sarangi F, Gerlach JH, Deuchars KL and Ling V (1987) Simultaneous expression of two P-glycoprotein genes in drug-sensitive Chinese hamster ovary cells. Mol Cell Biol 7: 4075-4081.
81. Endicott JA and Ling V (1989) The biochemistry of P-glycoproteinmediated multidrug resistance. Annu Rev Biochem 58: 137-171.
82. Endicott JA, Sarangi F and Ling V (1991) Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family. DNA Seq. 2: 89-101.
83. Eytan GD, Borgnia MJ, Regev R and Assaraf YG (1994) Transport of polypeptide ionophores into proteoliposomes reconstituted with rat liver P-glycoprotein. J Biol Chem 269: 26058-26065.
84. Eytan GD, Regev R and Assaraf YG (1996) Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. J Biol Chem 271: 3172-3178.
85. Ferry DR, Russell MA and Cullen MH (1992) P-glycoprotein possesses a 1,4 - dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca-alkaloid-selective binding site. Biochem Biophys Res Commun 188: 440-445.
86. Ferry DR, Malkhandi PJ, Russell MA and Kerr DJ (1995) Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49: 1851-1861.
87. Fine RL, Patel J and Chabner BA (1988) Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85: 582-586.
88. Fine RL, Chambers TC and Sachs CW (1996) P-glycoprotein, multidrug resistance and protein kinase C. Stem Cells 14: 47-55.
89. Fojo A, Akiyama S-I, Gottesman MM and Pastan I (1985) Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 45: 3002-3007.
90. Ford JM (1996) Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A: 991-1001.
91. Furuya KN, Gebhardt R, Schuetz EG and Schuetz JD (1994) Isolation of rat pgp3 cDNA: evidence for gender and zonal regulation of expression in the liver. Biochim Biophys Acta 1219: 636-644.
92. Garrigos M, Mir LM and Orlowski S (1997) Competitive and non-competitive inhibition of the multidrug-resistance- associated P-glycoprotein ATPase-further experimental evidence for a multisite model. Eur J Biochem 244: 664-673.
93. Georges E, Bradley G, Gariepy J and Ling V (1990) Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 87: 152-156.
94. Georges E, Tsuruo T and Ling V (1993) Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody. J Biol Chem 268: 1792-1798.
95. Germann UA (1993) Molecular analysis of the multidrug transporter. Cytotechnology 12: 33-62.
96. Germann UA, Chambers TC, Ambudkar SV, Pastan I and Gottesman MM (1995) Effects of phosphorylation of P-glycoprotein on multidrug resistance. J Bioenerg Biomembr 27: 53-61.
97. Germann UA (1996) P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944.
98. Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I and Gottesman MM (1996) Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 271: 1708-1716.
99. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J and Harding MW (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8: 125-140.
100. Gill DR, Hyde SC, Higgins CF, Valverde MA, Mintenig GM and Sepúlveda FV (1992) Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 71: 23-32.
101. Glavy JS, Horwitz SB and Orr GA (1997) Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein. J Biol Chem 272: 5909-5914.
102. Goldstein JL and Brown MS (1990) Regulation of the mevalonate pathway. Nature 343: 425-430.
103. Goodfellow HR, Sordini A, Ruetz S, Callaghan R, Gros P, McNaughton PA and Higgins CF (1996) Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 271: 13668-13674.
104. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427.
105. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA and Pastan I (1995) Genetic analysis of the multidrug transporter. Annu Rev Genet 29: 607-649.
106. Gottesman MM, Pastan I and Ambudkar SV (1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6: 610-617.
107. Greenberger LM, Yang CH, Gindin E and Horwitz SB (1990) Photoaffinity probes for the alpha 1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J Biol Chem 265: 4394-4401.
108. Greenberger LM, Lisanti CJ, Silva JT and Horwitz SB (1991) Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded mouse mdr1b. J Biol Chem 266: 20744-20751.
109. Greenberger LM (1993) Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domain-6 and domain-12. J Biol Chem 268: 11417-11425.
110. Gros P, Ben Neriah Y, Croop J and Housman DE (1986a) Isolation and characterization of a complementary DNA that confers multidrug resistance. Nature 323: 728-731.
111. Gros P, Croop J and Housman DE (1986b) Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47: 371-380.
112. Gros P, Croop J, Roninson IB, Varshavsky A and Housman DE (1986c) Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells. Proc Natl Acad Sci USA 83: 337-341.
113. Gros P, Raymond M, Bell J and Housman DE (1988) Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 8: 2770-2778.
114. Gros P, Dhir R, Croop J and Talbot F (1991) A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc Natl Acad Sci USA 88: 7289-7293.
115. Gupta S, Patel K, Singh H and Gollapudi S (1994) Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein. Cancer Lett 76: 139-145.
116. Gupta KP, Ward NE, Gravitt KR, Bergman PJ and O'Brian CA (1996) Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. J Biol Chem 271: 2102-2111.
117. Hamada H, Hagiwara K-I, Nakajima T and Tsuruo T (1987) Phosphorylation of the Mr 170 000 to 180 000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res 47: 2860-2865.
118. Hamada H and Tsuruo T (1988a) Characterization of the ATPase activity of the Mr 170 000 to 180 000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res 48: 4926-4932.
119. Hamada H and Tsuruo T (1988b) Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance - 170- to 180-kilodalton membrane glycoprotein is an ATPase. J Biol Chem 263: 1454-1458.
120. Hanna M, Brault M, Kwan T, Kast C and Gros P (1996) Mutagenesis of transmembrane domain 11 of P-glycoprotein by alanine scanning. Biochemistry 35: 3625-3635.
121. Hardy SP, Goodfellow HR, Valverde MA, Gill DR, Sepulveda V and Higgins CF (1995) Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. Embo J 14: 68-75.
122. Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SP and Kuwano M (1995) Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 71: 907-913.
123. Higgins CF (1992) ABC transporters - from microorganisms to man. Annu Rev Cell Biol 8: 67-113.
124. Higgins CF and Gottesman MM (1992) Is the multidrug transporter a flippase? Trends Pharmacol Sci 17: 18-21.
125. Higgins CF (1993) The ABC transporter channel superfamily - an overview. Semin Cell Biol 4: 1-5.
126. Higgins CF (1995) P-glycoprotein and cell volume-activated chloride channels. J Bioenerg Biomembr 27: 63-70.
127. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM and Sarkadi B (1993) Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268: 21493-21496.
128. Hoof T, Demmer A, Hadam MR, Riordan JR and Tummler B (1994) Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1. J Biol Chem 269: 20575-20583.
129. Horio M, Gottesman MM and Pastan I (1988) ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 85: 3580-3584.
130. Horio M, Chin K-V, Currier SJ, Goldenberg S, Williams C, Pastan I, Gottesman MM and Handler J (1989) Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J Biol Chem 264: 14880-14884.
131. Hsu SI, Lothstein L and Horwitz SB (1989) Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. J Biol Chem 264: 12053-12062.
132. Hu YP, Chapey C and Robert J (1996) Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Cancer Lett 109: 203-209.
133. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C and Bhalla K (1997) Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11: 253-257.
134. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gullagher MP, Gill DR, Hubbard RE and Higgins CF (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance, and bacterial transport. Nature 346: 362-365.
135. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR and Scheper RJ (1996) Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 65: 230-237.
136. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162.
137. Juvvadi SR, Glavy JS, Horwitz SB and Orr GA (1997) Domain organization of murine mdrlb P-glycoprotein: the cytoplasmic linker region is a potential dimerization domain. Biochem Biophys Res Commun 230: 442-447.
138. Kajiji S, Talbot F, Grizzuti K, Vandykephillips V, Agresti M, Safa AR and Gros P (1993) Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain-11 as a putative drug binding site. Biochemistry 32: 4185-4194.
139. Kajiji S, Dreslin JA, Grizzuti K and Gros P (1994) Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine 939/941. Biochemistry 33: 5041-5048.
140. Kamimoto Y, Gatmaitan Z, Hsu J and Arias IM (1989) The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem 264: 11693-11698.
141. Kane SE (1996) Multidrug resistance in cancer cells. Advances Drug Research 28: 181-252.
142. Kartner N, Evernden-Porelle D, Bradley G and Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820-823.
143. Kast C, Canfield V, Levenson R and Gros P (1995) Membrane topology of P-glycoprotein as determined by epitope insertion: transmembrane organization of the N-terminal domain of mdr3. Biochemistry 34: 4402-4411.
144. Kast C, Canfield V, Levenson R and Gros P (1996) Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence. J Biol Chem 271: 9240-9248.
145. Kessel D, Botterill V and Wodinsky I (1968) Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res 28: 938-941.
146. 185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 162: 224-231.
147. Kokubu N, Cohen D and Watanabe T (1997) Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotein. Biochem Biophys Res Commun 230: 398-401.
148. Kyriakis JM, Avruch, J (1996) Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 271: 24313-24316.
149. Lange Y (1994) Cholesterol movement from plasma membrane to rough endoplasmic reticulum. Inhibition by progesterone. J Biol Chem 269: 3411-3414.
150. Lee WP (1995) P-glycoprotein is hyperphosphorylated in multidrug resistant HOB1 lymphoma cells treated with overdose of vincristine. Biochim Biophys Acta 1245: 57-61.
151. Lelong IH, Padmanabhan R, Lovelace E, Pastan I and Gottesman MM (1992) ATP and GTP as alternative energy sources for vinblastine transport by P-170 in KB-V1 plasma membrane vesicles. FEBS Lett 304: 256-260.
152. Leveille-Webster CR and Arias IM (1995) The biology of the Pglycoproteins. J Membrane Biol 143: 89-102.
153. Levy D (1996) Membrane proteins which exhibit multiple topological orientations. Essays Biochem 31: 49-60.
154. Ling V (1995) P-glycoprotein: its role in drug resistance. Am J Med 99: 31S-34S.
155. Liu R and Sharom FJ (1996) Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry 35: 11865-11873.
156. Liu R and Sharom FJ (1997) Fluorescence studies on the nucleotide binding domains of the P-glycoprotein multidrug transporter. Biochemistry 36: 2836-2843.
157. Loo TW and Clarke DM (1993a) Functional consequences of phenylalanine mutations in the predicted transmembrane domain of p-glycoprotein. J Biol Chem 268: 19965-19972.
158. Loo TW and Clarke DM (1993b) Functional consequences of proline mutations in the predicted transmembrane domain of P-Glycoprotein. J Biol Chem 268: 3143-3149.
159. Loo TW and Clarke DM (1994a) Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. J Biol Chem 269: 7243-7248.
160. Loo TW and Clarke DM (1994b) Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 33: 14049-14057.
161. Loo TW and Clarke DM (1994c) Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. J Biol Chem 269: 7750-7755.
162. Loo TW and Clarke DM (1995a) Covalent modification of human P-glycoprotein mutants containing a single cysteine at either nucleotide-binding fold abolishes drug-stimulated ATPase activity. J Biol Chem 270: 22957-22961.
163. Loo TW and Clarke DM (1995b) Membrane topology of a cysteineless mutant of human P-glycoprotein. J Biol Chem 270: 843-848.
164. Loo TW and Clarke DM (1995c) P-glycoprotein: associations between domains and between domains and molecular chaperones. J Biol Chem 270: 21839-21844.
165. Loo TW and Clarke DM (1995d) Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities. J Biol Chem 270: 21449-21452.
166. Loo TW and Clarke DM (1996a) Inhibition of oxidative crosslinking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates. J Biol Chem 271: 27482-27487.
167. Loo TW and Clarke DM (1996b) The minimum functional unit of human P-glycoprotein appears to be a monomer. J Biol Chem 271: 27488-27492.
168. Loo TW and Clarke DM (1996c) Mutational analysis of the predicted first transmembrane segment of each homologous half of human P-glycoprotein suggests that they are symmetrically arranged in the membrane. J Biol Chem 271: 15414-15419.
169. Luckie DB, Krouse ME, Harper KL, Law TC and Wine JJ (1994) Selection for MDR1/P-glycoprotein enhances swelling-activated K+ and Cl- currents in NIH/3T3 cells. Am J Physiol 267: C650-C658.
170. Lum BL, Gosland MP, Kaubisch S and Sikic BI (1993) Molecular targets in oncology: Implications of the multidrug resistance gene. Pharmacotherapy 13: 88-109.
171. Ma LD, Marquardt D, Takemoto L and Center MS (1991) Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. J Biol Chem 266: 5593-5599.
172. Malkhandi J, Ferry DR, Boer R, Gekeler V, Ise W and Kerr DJ (1994) Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur J Pharmacol 288: 105-114.
173. Mellado W and Horwitz SB (1987) Phosphorylation of the multidrug resistance associated glycoprotein. Biochemistry 26: 6900-6904.
174. Metherall JE, Li H and Waugh K (1996a) Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis. J Biol Chem 271: 2634-2640.
175. Metherall JE, Waugh K and Li H (1996b) Progesterone inhibits cholesterol biosynthesis in cultured cells. Accumulation of cholesterol precursors. J Biol Chem 271: 2627-2633.
176. Mimura CS, Holbrook SR and Ames GF-L (1991) Structural model of the nucleotide-binding conserved component of periplasmic permeases. Proc Natl Acad Sci US. 88: 84-88.
177. Morris DI, Speicher LA, Ruoho AE, Tew KD and Seamon KB (1991) Interaction of forskolin with the P-glycoprotein multidrug transporter. Biochemistry 30: 8371-8379.
178. Morris DI, Greenberger LM, Bruggemann EP, Cardarelli C, Gottesman MM, Pastan I and Seamon KB (1994) Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. Mol. Pharmacol 46: 329-337.
179. Muller M, Bakos E, Welker E, Váradi A, Germann UA, Gottesman MM, Morse BS, Roninson IB and Sarkadi B (1996) Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein. J Biol Chem 271: 1877-1883.
180. Naito M and Tsuruo T (1992) Functionally active homodimer of P-glycoprotein in multidrug-resistant tumor cells. Biochem Biophys Res Commun 185: 284-290.
181. Naito M, Tsuge H, Kuroko C, Koyama T, Tomida A, Tatsuta T, Heike Y and Tsuruo T (1993) Enhancement of cellular accumulation of cyclosporin by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J Nat Cancer Inst 85: 311-316.
182. Ojima I, Duclos O, Dorman G, Simonot B, Prestwich GD, Rao S, Lerro KA and Horwitz SB (1995) A new paclitaxel photoaffinity analog with a 3-(4-benzoylphenyl)propanoyl probe for characterization of drug-binding sites on tubulin and P-glycoprotein. J Med Chem 38: 3891-3894.
183. Orlowski S, Mir LM, Belehradek J, Jr. and Garrigos M (1996) Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J 317: 515-522.
184. Orr GA, Han EK-H, Browne PC, Nieves E, O'Connor BM, Yang CP and Horwitz SB (1993) Identification of the major phosphorylation domain of murine mdr1b P-glycoprotein. J Biol Chem 268: 25054-25062.
185. 2-terminal protein kinase pathway in the cellular response to Adriamycin and other chemotherapeutic drugs. J Biol Chem 271: 30950-30955.
186. Oude Elferink RPJ and Groen AK (1995) The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. J Hepatol 23: 617-625.
187. Paulmichl M, Li Y, Wickman K, Ackerman M, Peralta E and Clapham D (1992) New mammalian chloride channel identified by expression cloning. Nature 356: 238-241.
188. Poloni F, Romagnoli G, Cianfriglia M and Felici F (1995) Isolation of antigenic mimics of MDR1-P-glycoprotein by phagedisplayed peptide libraries. Int J Cancer 61: 727-731.
189. Poruchynsky MS and Ling V (1994) Detection of oligomeric and monomeric forms of P-glycoprotein in multidrug resistant cells [published erratum appears in Biochemistry (1994) 33: 9032]. Biochemistry 33: 4163-4174.
190. Qian XD and Beck WT (1990) Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts. J Biol Chem 265: 18753-18756.
191. Ramachandra M, Ambudkar SV, Gottesman MM, Pastan I and Hrycyna CA (1996) Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. Mol Biol Cell 7: 1485-1498.
192. Rao US and Scarborough GA (1994) Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol 45: 773-776.
193. Rao US (1995) Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. J Biol Chem 270: 6686-6690.
194. Raviv Y, Pollard HB, Bruggemann EP, Pastan I and Gottesman MM (1990) Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265: 3975-3980.
195. Roepe PD (1995) The role of the MDR protein in altered drug translocation across tumor cell membranes. Biochim Biophys Acta 1241: 385-405.
196. Roninson IB (1991) Molecular and cellular biology of multidrug resistance in tumor cells. Plenum Publishing Corporation: New York.
197. Rosenberg MF, Callaghan R, Ford RC and Higgins CF (1997) Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 272: 10685-10694.
198. Ruetz S and Gros P (1994a) Functional expression of P-glycoprotein in secretory vesicles. J Biol Chem 269: 12277-12284.
199. Ruetz S and Gros P (1994b) Phospatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77: 1071-1081.
200. Ruetz S and Gros P (1995) Enhancement of Mdr2-mediated phosphatidylcholine translocation by the bile salt taurocholate. J Biol Chem 270: 25388-25395.
201. Sachs CW, Safa AR, Harrison SD and Fine RL (1995) Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 270: 26639-26648.
202. Sachs CW, Ballas LM, Mascarella SW, Safa AR, Lewin AH, Loomis C, Carroll FI, Bell RM and Fine RL (1996) Effects of sphingosine stereoisomers on P-glycoprotein phosphorylation and vinblastine accumulation in multidrug-resistant MCF-7 cells. Biochem Pharmacol 52: 603-612.
203. Saeki T, Ueda K, Tanigawara Y Hori R and Komano T (1993a) Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268: 6077-6080.
204. Saeki T, Ueda K, Tanigawara Y Hori R and Komano T (1993b) PGlycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett 324: 99-102.
205. Safa AR, Glover CJ, Meyets MB, Biedler JL and Felsted RL (1986) Vinblastine photoaffinity labeling of a high-molecular-weight surface membrane glycoprotein specific for multidrug-resistant cells. J Biol Chem 261: 6137-6140.
206. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL and Felsted RL (1987) Identification of the multidrug-resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 262: 7884-7888.
207. Safa AR (1988) Photoaffinity labeling of the multidrug-resistancerelated P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci USA 85: 7187-7191.
208. Safa AR, Mehta ND and Agresti M (1989) Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells with photoactive analogs of colchicine. Biochem Biophys Res Commun 161: 1402-1408.
209. Safa AR, Stern RK, Choi K, Agresti M, Tamai I, Mehta ND and Roninson IB (1990) Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly to Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA 87: 7225-7229.
210. Safa AR (1993) Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest 11: 46-56.
211. Safa AR, Roberts S, Agresti M and Fine RL (1994) Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells. Biochem Biophys Res Commun 202: 606-612.
212. Sarkadi B, Price EM, Boucher RC, Germann UA and Scarborough GA (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267: 4854-4858.
213. Sato W, Yusa K, Naito M and Tsuruo T (1990) Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 173: 1252-1257.
214. Schinkel AH, Roelofs MEM and Borst P (1991) Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 51: 2628-2635.
215. Schinkel AH, Kemp S, Dolle M, Rudenko G and Wagenaar E (1993) N-glycosylation and deletion mutants of the human MDR1 P-Glycoprotein. J Biol Chem 268: 7474-7481.
216. Schlemmer SR and Sirotnak FM (1994) Functional studies of P-glycoprotein in inside-out plasma membrane vesicles derived from murine erythroleukemia cells overexpressing MDR3. J Biol Chem 269: 31059-31066.
217. Schurr E, Raymond M, Bell JC and Gros P (1989) Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdrl cDNA. Cancer Res 49: 2729-2734.
218. Senior AE, Al-Shawi MK and Urbatsch IL (1995) The catalytic cycle of P-glycoprotein. FEBS Lett 377: 285-289.
219. Shapiro AB and Ling V (1994) ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. J Biol Chem 269: 3745-3754.
220. Shapiro AB and Ling V (1995) Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 270: 16167-16175.
221. Sharma S and Rose D (1995) Cloning, overexpression, purification, and characterization of the carboxyl-terminal nucleotide binding domain of P-glycoprotein. J Biol Chem 270: 14085-14093.
222. Sharom FJ, Yu X and Doige CA (1993) Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem 268: 24197-24202.
223. Sharom FJ, Yu X, DiDiodato G and Chu JW (1996) Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. Biochem J 320: 421-428.
224. Shen D-W, Cardarelli C, Hwang J, Cornwell M, Richert N, Ishii S, Pastan I and Gottesman MM (1986) Multiple drug resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, Adriamycin or vinblastine show changes in expression of specific proteins. J Biol Chem 261: 7762-7770.
225. Shimabuku AM, Nishimoto T, Ueda K and Komano T (1992) P-glycoprotein-ATP hydrolysis by the N-terminal nucleotidebinding domain. J Biol Chem 267: 4308-4311.
226. Shustik C, Dalton W and Gros P (1995) P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 16: 1-78.
227. Shyamala V, Baichwald V, Beall E and Ames GF-L (1991) Structure-function analysis of the histidine permease and comparison with cystic fibrosis mutations. J Biol Chem 266: 18714-18719.
228. Silverman JA, Raunio H, Gant TW and Thorgeirsson SS (1991) Cloning and characterization of a member of the rat multidrug resistance (mdr) gene family. Gene 106: 229-236.
229. Skach WR and Lingappa VR (1993) Amino-terminal assembly of human P-glycoprotein at the endoplasmic reticulum is directed by cooperative actions of two internal sequences. J Biol Chem 268: 23552-23561.
230. Skach WR, Calayag MC and Lingappa VR (1993) Evidence for an alternate model of human P-Glycoprotein structure and biogenesis. J Biol Chem 268: 6903-6908.
231. Skach WR and Lingappa VR (1994) Transmembrane orientation and topogenesis of the third and fourth membrane-spanning regions of human P-glycoprotein (MDR1).Cancer Res 54: 3202-3209.
232. Skovsgaard T, Nielsen D, Maare C and Wassermann K (1994) Cellular resistance to cancer chemotherapy. Int Rev Cytology 156: 77-157.
233. Slapak CA, Mizunuma N and Kufe DW (1994) Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 84: 3113-3121.
234. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, von Deemter L, Mol CAAM, Ottenhofer R, van der Lugt NMT, van Roon MA, van der Valk MA, Offerhaus GJA, Berns AJM and Borst P (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451-462.
235. Smit JJ, Schinkel AH, Mol CA, Majoor D, Mooi WJ, Jongsma AP, Lincke CR and Borst P (1994) Tissue distribution of the human MDR3 P-glycoprotein [see comments] [published erratum appears in Lab Invest (1995) 72:following table of contents]. Lab Invest 71: 638-649.
236. Smith CD and Zilfou JT (1995) Circumvention of P-glycoproteinmediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem: 28145-28152.
237. Staats J, Marquardt D and Center MS (1990) Characterization of a membrane-associated protein kinase of multidrug- resistant HL60 cells which phosphorylates P-glycoprotein. J Biol Chem 265: 4084-4090.
238. Sugimoto Y and Tsuruo T (1991) Development of multidrug resistance in rodent cell lines. In: Roninson IB (ed) Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells (pp. 57-70). Plenum Publishing Corporation: New York.
239. Tamai I and Safa AR (1991) Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 266: 16796-16800.
240. Tang-Wai DE, Kajiji S, DiCapua F, de Graaf D, Roninson IB and Gros P (1995) Human (MDR1) and mouse (mdrl, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 34: 32-39.
241. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972.
242. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y (1982) Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730-4733.
243. Ueda K, Cardarelli C, Gottesman MM and Pastan I (1987) Expression of a full-length cDNA for the human 'MDR1' (Pglycoprotein) gene confers multidrug resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84: 3004-3008.
244. Ueda K, Okamura N, Hirai M, Tanigawara Y Saeki T, Kioka N, Komano T and Hori R (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267: 24248-24252.
245. Urbatsch IL, Al-Shawi MK and Senior AE (1994) Character-ization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry 33: 7069-7076.
246. Urbatsch IL and Senior AE (1995) Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein. Arch Biochem Biophys 316: 135-140.
247. Urbatsch IL, Sankaran B, Bhagat S and Senior AE (1995) Both P-glycoprotein nucleotide binding sites are catalytically active. J Biol Chem 270: 26956-26961.
248. Valverde MA, Diáz M, Sepúlveda FV, Gill DR, Hyde SC and Higgins CF (1992) Volume-regulated chloride channels associated with the human multidrug resistance P-glycoprotein. Nature 355: 830-833.
249. Van der Bliek AM, Baas F, Ten Houte de Lange T, Kooiman PM, Van der Velde-Koerts T and Borst P (1987) The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J 6: 3325-3331.
250. Van der Bliek AM, Kooiman PM, Schneider C and Borst P (1988) Sequence of mdr3 cDNA, encoding a human P-glycoprotein. Gene 71: 401-411.
251. Van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, Kulper CM, Tsuruo T, Lankelma J, Meijer CJL, Pinedo HM and Scheper RJ (1990) Ann Oncol 1: 56-64.
252. Van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P and van Meer G (1996) MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87: 507-517.
253. Wadkins RM and Roepe PD (1997) Biophysical aspects of P-glycoprotein-mediated multidrug resistance. Int Rev Cytol 171: 121-165.
254. Walker JE, Saraste M, Runswick MJ and Gay NJ (1982) Distantly related sequences in the a- and b-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1: 945-951.
255. Weinstein RS, Kuszak JR, Kluskens LF and Coon JS (1990) P-glycoproteins in pathology: the multidrug resistance gene family in humans. Human Path 21: 34-48.
256. Wine JJ and Luckie DB (1996) Cell-volume regulation: P-glycoprotein-a cautionary tale. Curr Biol 6: 1410-1412.
257. Worrel RT, Butt AG, Cliff WH and Frizzel RA (1989) A volumesensitive chloride conductance in human colonie cell line T84. Am J Physiol 256: C1111-C1119.
258. Wright LC, Dyne M, Holmes KT and Mountford CE (1985) Phospholipid and ether linked phospholipid content alter with cellular resistance to vinblastine. Biochem Biophys Res Commun 133: 539-545.
259. Yang C-PH, DePinho SG, Greenberger LM, Arceci RJ and Horwitz SB (1989) Progesterone interacts with P-glycoprotein in multidrug resistant cells and in the endometrium of gravid uterus. J Biol Chem 264: 782-788.
260. Yang JM, Chin KV and Hait WN (1995) Involvement of phospholipase C in heat-shock-induced phosphorylation of P-glycoprotein in multidrug resistant human breast cancer cells. Biochem Biophys Res Commun 210: 21-30.
261. Yang JM, Chin KV and Hait WN (1996) Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Cancer Res 56: 3490-3494.
262. Yoshimura A, Kuwazuru Y, Sumizawa T, Ichikawa M, Ikeda S, Ueda T and Akiyama S-I (1989) Cytoplasmic orientation and two-domain structure of the multidrug transporter, P-glycoprotein, demonstrated with sequence-specific antibodies. J BiolChem264: 16282-16291.
263. Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Cowan JH and Glazer RI (1991) Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3: 181-188.
264. Yusa K and Tsuruo T (1989) Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49: 5002-5006.
265. Zhang J-T and Ling V (1991) Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. J Biol Chem 266: 18224-18232.
266. Zhang JT, Duthie M and Ling V (1993) Membrane topology of the N-terminal half of the hamster P-glycoprotein molecule. J Biol Chem 268: 15101-15110.
267. Zhang JT and Ling V (1995) Involvement of cytoplasmic factors regulating the membrane orientation of P-glycoprotein sequences. Biochemistry 34: 9159-9165.
268. Zhang JT, Lee CH, Duthie M and Ling V (1995a) Topological determinants of internal transmembrane segments in P-glycoprotein sequences. J Biol Chem 270: 1742-1746.
269. Zhang X, Collins KI and Greenberger LM (1995b) Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1. J Biol Chem 270: 5441-5448.
270. Zhang M, Wang G, Shapiro A and Zhang JT (1996) Topological folding and proteolysis profile of P-glycoprotein in membranes of multidrug-resistant cells: implications for the drug- transport mechanism. Biochemistry 35: 9728-9736.
271. Ursula A. Germann, Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, Massachusetts 02139-4242, U.S.A. Germann@macnet.vpharm.com